Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rockland Immunochemicals has entered into a new licensing agreement with LIMR Development (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR).
Subscribe to our email newsletter
Rockland will market LDI’s portfolio of LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.
LIMR president and CEO George Prendergast said: "We are proud of the achievement of LDI to generate an agreement with Rockland to commercialize the high-quality research antibodies developed at LIMR."
Rockland president and CEO James Fendrick said: "We are proud to bring the unique scientific and commercial opportunities of the LIMR/LDI/Rockland collaboration to the global research community."